Literature DB >> 12036724

Bioavailability and in vitro oesophageal sticking tendency of hydroxypropyl methylcellulose capsule formulations and corresponding gelatine capsule formulations.

Outi Honkanen1, Pia Laaksonen, Janne Marvola, Sari Eerikäinen, Raimo Tuominen, Martti Marvola, Laaksonen Pia, Marvola Janne, Eerikäinen Sari, Tuominen Raimo, Marvola Martti.   

Abstract

The overall aim of the present study was to widen our knowledge about the biopharmaceutical behaviour of novel hydroxypropyl methylcellulose (HPMC)-based two-piece capsules by comparing them with the classic hard gelatine capsules. Firstly, the tendency of the HPMC capsules to stick to isolated porcine oesophageal preparation was evaluated. The force needed to detach the HPMC capsules from the oesophagus was significantly lower than that for the gelatine capsules (P<0.001), which is evidently an advantage of this new dosage form. The second aim was to investigate the possibility of preparing sustained-release capsules using different powdered HPMCs as diluents (K100, K4M and K15M) and the effect of the molecular weight of HPMC powder on the in vitro and in vivo behaviour of the capsules. In addition to peroral drug administration also rectal dosing was applied. Two groups of eight healthy volunteers participated in randomised, cross-over, single-dose studies. One group was administered capsules orally and the other rectally. There were no marked differences in the bioavailability properties of either the oral or rectal HPMC capsules containing ibuprofen as model drug as compared with corresponding gelatine capsule formulations. Using different viscosity grades of HPMC powders as diluents it was possible to control the absorption rate of the model drug both from gelatine and HPMC capsules as far as the oral route was concerned. After rectal administration there were no statistically significant differences between the formulations containing different grades of HPMC powder. Only partial correlation was observed between the results of the bioavailability studies and the in vitro dissolution studies. From a biopharmaceutical point of view these two shell materials can be regarded as interchangeable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036724     DOI: 10.1016/s0928-0987(02)00032-5

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  In vitro and in vivo pharmacoscintigraphic evaluation of ibuprofen hypromellose and gelatin capsules.

Authors:  Ewart T Cole; Robert A Scott; Dominique Cade; Alyson L Connor; Ian R Wilding
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

Review 2.  Bioadhesive dosage forms for esophageal drug delivery.

Authors:  Hannah Batchelor
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

3.  Barrier Effect of a New Topical Agent on Damaged Esophageal Mucosa: Experimental Study on an ex vivo Swine Model.

Authors:  Roberta Salaroli; Domenico Ventrella; Chiara Bernardini; Alberto Elmi; Augusta Zannoni; Maria Laura Bacci; Monica Forni; Fiorella Calanni; Antonella Ferrieri; Fabio Baldi
Journal:  Clin Exp Gastroenterol       Date:  2020-11-13

4.  Barrier effect of Esoxx(®) on esophageal mucosal damage: experimental study on ex-vivo swine model.

Authors:  Massimo P Di Simone; Fabio Baldi; Valentina Vasina; Fabrizio Scorrano; Maria Laura Bacci; Antonella Ferrieri; Gilberto Poggioli
Journal:  Clin Exp Gastroenterol       Date:  2012-06-11

5.  Comparison of In Vitro and In Vivo Results Using the GastroDuo and the Salivary Tracer Technique: Immediate Release Dosage Forms under Fasting Conditions.

Authors:  Maximilian Sager; Philipp Schick; Magdalena Mischek; Christian Schulze; Mahmoud Hasan; Marie-Luise Kromrey; Hassan Benameur; Martin Wendler; Mladen Vassilev Tzvetkov; Werner Weitschies; Mirko Koziolek
Journal:  Pharmaceutics       Date:  2019-12-07       Impact factor: 6.321

6.  Generalized in vitro-in vivo relationship (IVIVR) model based on artificial neural networks.

Authors:  Aleksander Mendyk; Paweł K Tuszyński; Sebastian Polak; Renata Jachowicz
Journal:  Drug Des Devel Ther       Date:  2013-03-27       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.